Outsourcing Outlook - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing Outlook

CMO Industry Thins Out

October 2, 2014

Pharmaceutical Technology

The trend of exits from the CMO industry looks to be gaining momentum.

Targeting Different Off-Shore Destinations

September 2, 2014

Pharmaceutical Technology

Annual study shows geographic proximity not a factor in CMO selection.

Outsourcing No Longer Just for Cost-Cutting

June 2, 2014

Pharmaceutical Technology

With budgets growing, clients see CMOs' costs as less crucial.

Stuck in Neutral

May 2, 2014

Pharmaceutical Technology

The CMO industry's value proposition is limiting its market penetration.

Biopharma Outsourcing Activities Update

April 2, 2014

Pharmaceutical Technology

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Under New Ownership

March 2, 2014

Pharmaceutical Technology

Changes in company ownership shake up the CMO industry.

Novel Expression Systems Opening CMO Opportunities

February 2, 2014

Pharmaceutical Technology

CMOs may find opportunities in alternative expression services.

R&D in Transition

January 2, 2014

Pharmaceutical Technology

The R&D model is in transition and creating new demands on contract services providers.

Climate Change in Outsourcing

December 2, 2013

Pharmaceutical Technology

Ongoing changes create new opportunities for CROs and CMOs.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here